Precision medicine approaches needed in oncology to match evolving SoC
As the standard of care (SoC) for new drugs in oncology continues to improve, trials need to be designed with…
All articles by Jam Bensilum
Jam Bensilum
Jam Bensilum is a healthcare and pharmaceutical reporter. She has a background in medical communications with extensive experience across both medical affairs and publications. She holds an MSc in Molecular Medicine from Imperial College London and has interests in oncology, infectious disease, biologics, mental health and women’s health.
-
-
Can regulatory reform unearth LATAMs untapped potential for drug development?
Pivotal regulatory reform, digitalisation and improved regional cooperation are transforming countries such as Argentina, Brazil, Mexico, and other Latin America…
-
Utilising real-world data to overcome challenges in rare disease research
Innovative approaches like synthetic control arms based on real-world data may help overcome the unique challenges faced in clinical trials…
-
Remote monitoring could reduce patient burden and improve outcomes
As processes in drug development become increasingly digitalised, novel technologies that track progress of patient cohorts in real-time may allow…
-
Redefining clinical trials in oncology and rare diseases across the Europe
Later this month, experts from the pharmaceutical and biotechnology industry and patient advocacy space will gather in Munich, Germany, to…
-
ESMO 2025: Anticipated Phase II data debut for Eikon’s NSCLC candidate
Eyes will be on Eikon’s upcoming data readout for its toll-like receptors 7 and 8 (TLR7/8) co-agonist, as the company…
-
Gilead to present data on potential first weekly oral treatment for HIV
Gilead Sciences will present long-term data on a novel long-acting oral combination treatment for HIV at a major upcoming conference.…
-
Harmony’s cannabidiol drug flops in pivotal Fragile X Syndrome trial
Harmony Biosciences’ transdermal cannabidiol ZYN002 suffered a setback as a Phase III trial failed to meet the primary endpoint in…
-
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton…
-
Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer
Imunon’s IL-12 gene therapy IMImuNN-001 converts the tumour microenvironment from “cold” to “hot” by both, halting immunosuppressive makers, and stimulating…